Systematic review and meta-analysis: evaluating response to empiric anti-TNF dose intensification for secondary loss of response in Crohn’s disease

Ashish Srinivasan, Robert Gilmore, Daniel van Langenberg and Peter De Cruz

Abstract
Introduction: Anti-tumor necrosis factor (TNF) dose intensification represents an effective method of overcoming secondary loss of response (LOR); however, a subset of patients may not respond (tertiary non-response), or fail to demonstrate durable response (tertiary LOR) to intensified dosing. This systematic review and meta-analysis aimed to evaluate these outcomes to determine the clinical effectiveness of empiric dose intensification in Crohn’s disease.

Methods: Multiple databases including MEDLINE and EMBASE were interrogated to identify studies that reported outcomes following anti-TNF dose intensification to address secondary LOR in Crohn’s disease. Studies that used anti-TNF levels as the primary basis for dose intensification were excluded. Studies that reported (1) tertiary response and tertiary non-response within 6 months or (2) tertiary response and tertiary LOR beyond 6 months, were pooled using a random effects model with risk ratio (RR) derived, quantifying the effect of each comparison.

Results: Twenty-six studies reported outcomes following anti-TNF dose intensification to address secondary LOR. Short-term response within 12 weeks of any dose-intensification strategy was 33–90%, while sustained response (≥48 weeks) was achieved in 25–85%. Tertiary non-response occurred in up to 45% of intensified patients within 6 months of anti-TNF dose intensification, while tertiary LOR beyond 6 months occurred in up to 64% of patients. Tertiary response was more likely than tertiary non-response within 6 months (RR 2.58, 95% CI [1.76, 3.79], I² = 82%, 12 studies), while sustained response beyond 6 months compared to tertiary LOR (RR 1.10 [0.75, 1.61], I² = 85%, 7 studies) was less convincing.

Conclusion: Although anti-TNF dose intensification is clinically effective in patients with Crohn’s disease, particularly within the first 6 months, a proportion of patients will fail to demonstrate short-term and/or sustained clinical response. Hence, clinical reassessment following anti-TNF dose intensification, particularly beyond 6 months, remains important to differentiate between effective and ineffective dose-intensification strategies.

Keywords: adalimumab, anti-TNF, Crohn’s disease, dose intensification, infliximab, loss of response

Introduction
Despite the efficacy of anti-tumor necrosis factor (TNF) agents in Crohn’s disease, up to 30% of patients exhibit primary non-response, with a further 46% of anti-TNF responders demonstrating features of secondary loss of response (LOR) within 12 months of anti-TNF initiation.1–3 Several studies have demonstrated the clinical effectiveness of...
anti-TNF dose intensification to overcome LOR using dosing strategies including one or more of: shortening the interval between anti-TNF doses; increasing the baseline anti-TNF dose while maintaining the dosing interval, and; anti-TNF re-induction.4–7

Two recent systematic reviews, one of which also undertook a meta-analysis, evaluated the clinical effectiveness of anti-TNF dose intensification to address LOR across Crohn’s disease and ulcerative colitis.8,9 While comprehensive in their approach, neither review distinguished between anti-TNF dose intensification undertaken to address secondary LOR and anti-TNF dose intensification undertaken to address pooled primary non-response and secondary LOR. It is, however, important to differentiate between both of these entities, given the disparate clinical effectiveness of anti-TNF dose intensification between primary responders and primary non-responders. Thus, targeted evaluation of the clinical effectiveness of anti-TNF dose intensification to address secondary LOR is needed.

Moreover, amid the growing use of intensified anti-TNF dosing to address LOR in Crohn’s disease, it remains important that clinicians recognise that a subset of patients may not respond, or fail to demonstrate durable response to intensified anti-TNF dosing. These outcomes, notionally termed, ‘tertiary non-response’ and ‘tertiary LOR’, have not previously been well described, nor compared with tertiary response (Figure 1). Hence, in addition to evaluating the clinical effectiveness of anti-TNF dose intensification to address secondary LOR, this review will evaluate outcomes such as ‘tertiary non-response’ and ‘tertiary LOR’ reflective of ineffective dose intensification. Factors associated with these outcomes will also be described.

Definitions
Anti-TNF dose intensification was defined as empiric dose intensification based on clinical symptoms as judged by the treating clinician, with or without objective disease assessment. Studies that used serum anti-TNF trough levels in the absence of clinical symptoms as the primary basis for directing therapeutic intervention following secondary LOR, were excluded. This decision was made to minimise heterogeneity in baseline disease activity and its impact on subsequent assessments of tertiary response, non-response and LOR following anti-TNF dose intensification.

Anti-TNF dose intensification was defined as one or more of: shortening the interval between anti-TNF doses; increasing the baseline anti-TNF dose while maintaining the dosing interval, and; anti-TNF re-induction. Tertiary response was defined as the number of patients demonstrating clinical response following anti-TNF dose intensification undertaken to address secondary LOR relative to all patients who underwent anti-TNF dose intensification. Tertiary non-response was defined as lack of response occurring within 6 months of anti-TNF dose intensification. Tertiary LOR was defined as LOR occurring more than 6 months following anti-TNF dose intensification.

Methods
This systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines; however, it was not prospectively registered on PROSPERO.10

Selection criteria
Studies eligible for inclusion in this systematic review included clinical trials (randomised/non-randomised) and cohort studies (retrospective/prospective) that investigated: (a) Population: adult patients with Crohn’s disease who demonstrated primary response to adalimumab, certolizumab, or infliximab; (b) Intervention: empiric adalimumab, certolizumab, or infliximab dose intensification to address secondary LOR following standard induction and maintenance dosing; (c) Outcome: proportion demonstrating clinical response/remission, non-response and LOR following anti-TNF dose intensification. Studies that did not clearly define criteria for secondary LOR prior to dose intensification and/or clinical response/remission following anti-TNF dose intensification, were excluded. Similarly, studies that reported outcomes following anti-TNF dose intensification to address combined primary non-response and secondary LOR were reported separately, unless outcomes specific to secondary LOR were reported or could be imputed.
intensification were deemed to reflect dose intensification undertaken to address primary non-response and were thus reported separately.

Search strategy
A search of the medical literature published in English was conducted, using Ovid MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews through to 30 July 2021. Search algorithms included a combination of terms reflecting the disease of interest (Crohn(s) disease) in combination with treatment (anti-TNF, anti-TNF, TNF-alpha, adalimumab, certolizumab pegol, or infliximab), anti-TNF dosing regimen (intensification/escalation) and outcome (response/ LOR) of interest without restriction. Two authors (AS/RG) independently reviewed titles and abstracts of studies identified by the search and excluded those that were clearly unrelated on the basis of pre-specified inclusion and exclusion criteria. This process was undertaken with the assistance of the Covidence software programme. Full-text of selected articles was appraised to determine suitability for inclusion, with conflicts in study selection resolved by consensus and referring back to the original article, in consultation with a senior investigator (PDC). The reference lists of relevant studies were manually searched to identify additional publications of relevance.

Data synthesis and statistical analysis
Systematic review. The primary outcome of interest was tertiary response, that is, the proportion of patients demonstrating clinical response following anti-TNF dose intensification to address secondary LOR. Tertiary non-response, tertiary LOR and clinical remission following anti-TNF dose intensification were also assessed. Factors associated with these outcomes were also evaluated. Where studies reported outcomes following several dose-intensification strategies, outcomes were described collectively, based on anti-TNF, and per dose-intensification strategy, where possible. Studies in which anti-TNF dose intensification was undertaken to address both primary non-response and secondary LOR were reported separately.

Meta-analysis. The purpose of the meta-analysis was to evaluate the clinical effectiveness (tertiary response) of anti-TNF dose intensification against measures of clinical ineffectiveness (tertiary non-response /tertiary LOR). Hence studies that reported (1) tertiary response and tertiary non-response within 6 months or (2) tertiary response and tertiary LOR beyond 6 months, were included in the meta-analysis.

Data were combined to provide risk ratio (RR) with 95% confidence intervals (CIs) to summarise the effect of each comparison using a statistical significance threshold of p value < 0.05. Study heterogeneity was analysed using the I² statistic: with heterogeneity thresholds as follows: not important (I² < 40%), moderate (40–75%), and considerable (>75%). A Begg’s funnel plot was used to estimate the possibility of publication bias. Sensitivity analyses were performed for each meta-analysis subgroup by excluding studies that were identified as potentially introducing a critical risk of bias that could likely modify the outcome. Data were analysed using Review Manager (version 5.4).

Data extraction
The following characteristics were extracted from each eligible study: first author name, year of
publication, country where study was undertaken, study design, number of patient who were dose intensified, anti-TNF agent, dose-intensification strategy, duration of anti-TNF therapy prior to dose intensification, proportion on immunomodulator co-therapy at dose intensification, proportion with prior biologic failure at baseline, and proportion with perianal disease at baseline. Key study definitions including the basis for secondary LOR prior to anti-TNF dose intensification, basis for clinical response/remission following anti-TNF dose intensification, and the basis for clinical non-response/LOR following dose intensification were also documented. Finally, outcome measures pertaining to the proportion of patients demonstrating clinical response/remission and clinical non-response/LOR following dose intensification along with corresponding timepoints were recorded.

**Risk of bias assessment**

The methodological quality of all studies was assessed by two authors (AS and RG) with agreement reached by consensus if discrepancies arose. Each randomised controlled trial (RCT) was assessed using the Cochrane Collaboration tool, evaluating bias across the several domains including selection bias, reporting bias, performance bias, detection bias, attrition bias, and other bias. Similarly, observational studies were evaluated using the Newcastle–Ottawa Scale (NOS), with the quality of each study evaluated independently. Representativeness of the exposed cohorts, ascertainment of exposure, demonstration that the outcome of interest was not present at start of study, assessment of the outcome, and adequacy of the follow-up were assessed for each included study. Two criteria of the NOS, namely selection of the non-exposed cohort and comparability of the cohorts, were not used because cohorts not exposed to intensified anti-TNF therapy were not included.

**Results**

**Search results**

Following removal of duplicate records, 1024 articles were identified for assessment (Figure 2). Records deemed irrelevant or not suitable based on predetermined inclusion criteria were discarded. A total of 148 articles were retrieved for detailed evaluation, with 34 eligible studies included in the systematic review. Excluded based on title and/or abstracts review included 876 articles:
- Anti-TNF but not related to dose optimisation = 332
- Review: systematic, narrative, editorial = 178
- Predominantly paediatric population = 133
- Not Crohn’s disease related = 72
- Non-TNF biologic = 52
- Not Anti-TNF related = 36
- Case-report/Case-series = 25
- Proactive TDM dose optimisation = 28
- Basic Science = 20

Outcomes following dose intensification not defined = 51
- Unable to differentiate between IBD-subtypes = 31
- Basis for secondary loss of response not defined = 16
- Anti-TNF dose intensification for primary non response = 15
- Non-English = 1

**Figure 2.** Study selection flowchart as at 30 July 2021.
excluded, leaving 148 articles for detailed evaluation. We identified 34 eligible full-text articles of adult patients with Crohn’s disease that underwent anti-TNF dose intensification to address secondary LOR, comprising 3 RCTs, 3 post hoc analyses of RCTs, 7 prospective observational studies, and 21 retrospective studies (Table 1). We identified 34 eligible full-text articles of adult patients with Crohn’s disease that underwent anti-TNF dose intensification to address secondary LOR, comprising 3 RCTs, 3 post hoc analyses of RCTs, 7 prospective observational studies, and 21 retrospective studies (Table 1).4–7,15–45 Thirteen studies reported outcomes following infliximab dose intensification, 15 studies reported outcomes following adalimumab dose intensification, and six following both adalimumab and infliximab dose intensification. No studies evaluating certolizumab dose intensification met eligibility criteria.

Assessment of bias

The risk of bias assessments for RCTs and observational studies are presented in Supplementary Tables 1 and 2, respectively. Of three included RCTs, the study by Watanabe et al.37 was identified as potentially subject to selection bias owing to insufficient description of the randomisation and allocation concealment processes, while the studies by Steenholdt et al.15,29 were subject to detection bias as outcome assessment was not blinded, thus potentiating a higher risk of bias. Most observational studies exhibited a low to moderate risk of bias when applying the modified NOS scale (out of 6). Notably, observational studies were largely retrospective in design, with study outcomes generally present at study outset, reflecting an obvious source of bias.

Systematic review

Defining LOR prior to anti-TNF dose intensification

Clinical disease assessment. The definition of LOR prior to anti-TNF dose intensification was heterogeneous (Table 2). Several studies incorporated definitions based on validated clinical indices including the Crohn’s Disease Activity Index (CDAI) and Harvey–Bradshaw Index (HBI); however, disease activity thresholds associated with clinical LOR prior to dose intensification were variable.7,15–17,20,22,23,25,27,29,35–39 Eleven studies incorporated assessments of CDAI into the definition of LOR, with four studies documenting absolute CDAI thresholds.15–17,20,22,25,27,29,35,37,38 Four studies incorporated assessments of HBI into the definition of LOR, each documenting one or both of an absolute HBI threshold and/or change from baseline HBI, reflective of clinical LOR.7,23,36,39 The remaining studies ostensibly relied on physician-determined clinical deterioration, or definitions of symptomatic disease that did not incorporate validated clinical indices, to define LOR prior to anti-TNF dose intensification.

Objective disease assessment. Six studies required both clinically active disease based on clinical indices (CDAI or HBI) and objective disease activity defined as one or more of elevated C-reactive protein (CRP), faecal calprotectin, evidence of radiologic, and/or endoscopic inflammation.7,17,20,23,38,39 An additional eight studies required physician-determined symptomatic disease plus objectively assessed disease activity prior to anti-TNF dose intensification.6,21,26,28,32,41,42,45

Indication for anti-TNF dose intensification. Outcomes across eight studies did not differentiate between anti-TNF dose intensification undertaken to address primary non-response and secondary LOR.30,33–37,40,41 The remaining 26 studies reported clinical outcomes following anti-TNF dose intensification specifically undertaken to address secondary LOR.

Anti-TNF dose-intensification strategies

Of 34 eligible studies, clinical outcomes following anti-TNF dose intensification were reported across 45 patient cohorts, comprising 23 infliximab cohorts, 17 adalimumab cohorts, and 5 pooled adalimumab/infliximab cohorts. Thirty-seven cohorts reported outcomes following anti-TNF dose intensification to address secondary LOR, while eight cohorts reported pooled outcomes following anti-TNF dose intensification for primary non-response and/or secondary LOR, and were thus reported separately.

Infliximab dose intensification

Infliximab dose intensification was undertaken exclusively for secondary LOR across 17 of 19 eligible studies, with all but one study including patients who were anti-TNF experienced. Several studies evaluated more than one dose-intensification regimen, including infliximab 5 mg/kg 4–7 weekly (n = 10), infliximab 10 mg/kg 8 weekly or 5 mg/kg 4 weekly (n = 17), high-dose infliximab (≥10 mg/kg, 4–7 weekly) (n = 5) and infliximab re-induction (n = 2).7,15,17,19,21–30 These regimens
| Author (year) | Study design (country) | Anti-TNF agent intensified (number intensified) | Anti-TNF duration prior to dose intensification | Immuno modulator co-therapy (%) | Prior biologic failure (%) | Perianal disease (%) |
|--------------|-----------------------|---------------------------------------------|---------------------------------------------|--------------------------------|--------------------------|---------------------|
| Rutgeerts et al. [2004] | Prospective Multi-centre Randomised control trial (International) | Infliximab [58] | NR | 27%* | No | NR |
| Chaparro et al. [2011] | Retrospective Multi-centre Observational (Spain) | Infliximab [127] | NR | 95%* | No | 45%* |
| Hibi et al. [2012] | Prospective Multi-centre Observational (Japan) | Infliximab [18] | NR | 16%* | No | NR |
| Kopylov et al. [2011] | Retrospective Multi-centre Observation (Europe) | Infliximab [94] | Median 4 ± 5.7 infusions (range 1–24) | 59% | No | 39% |
| Chaparro et al. [2012] | Retrospective Multi-centre Observational (Spain) | Infliximab [33] | Median 12 months (IQR = 13.5 months) | 76% | No | 16% |
| Katz et al. [2012] | Retrospective Multi-centre Observations (Europe, USA, Israel) | Infliximab [168] | Median 6 infusions | 71% | 3% | 49% |
| Lin et al. [2012] | Retrospective Single-centre Observational (USA) | Infliximab [30] | NR | 53% | No | 30% |
| Steenholdt et al. [2014] | Prospective Multi-centre Randomised Control Trial (Denmark) | Infliximab [36] | Mean 12 infusions (range 4–37) | 39% | No | 8% |
| Hendler et al. [2015] | Retrospective Single-centre Observation (USA) | Infliximab [86] | NR | 49% | 31% | 48% |
Table 1. (Continued)

| Author (year) | Study design (country) | Anti-TNF agent intensified (number intensified) | Anti-TNF duration prior to dose intensification | Immune modulator co-therapy (%) | Prior biologic failure (%) | Perianal disease (%) |
|---------------|------------------------|-----------------------------------------------|-----------------------------------------------|-------------------------------|--------------------------|----------------------|
| **Nagata et al.**\(^{20}\) [2015] | Retrospective Single-centre Observation (Japan) | Infliximab [26] | Mean 32 months [range 8–89] | 34% | No | NR |
| **Steenholdt et al.**\(^{19}\) [2015] | Prospective Multi-centre Randomised control trial (Denmark) | Infliximab [36] | Mean 12 infusions [range 4–37] | 39% | No | 8% |
| **Suzuki et al.**\(^{14}\) [2015] | Prospective Multi-centre Observational (Japan) | Infliximab [39] | Median 1.7 years [range 0.3–6.0] | 33% | No | NR |
| **Dreesen et al.**\(^{19}\) [2018] | Retrospective Single-centre Observational (Belgium) | Infliximab [103] | 10 mg/kg 8-weekly: median 18 months [range 8–70] 5 mg/kg, interval shortening median 12 months [range 7–19] 10 mg/kg + interval shortening median 17 months [range 9–64] | 38% | No | NR |
| **Adalimumab** |  |  |  |  |  |  |
| **Colombel et al.**\(^{31}\) [2009] | Prospective Multi-centre Randomised control trial (International) | Adalimumab [40] | NR | 43%\(^{\text{a}}\) | 51%\(^{\text{a}}\) | 11.5%\(^{\text{a}}\) |
| **Karmiris et al.**\(^{32}\) [2009] | Retrospective Single-centre Observational (Belgium) | Adalimumab [70] | Median 14 weeks [range 11–24] | 37%\(^{\text{a}}\) | 100% | 11% |
| **Bultman et al.**\(^{33}\) [2012] | Retrospective Single-centre Observational (Netherlands) | Adalimumab [46] | Median 21 weeks [range 4–105] | 46% | 65% | 41% |
| **Panaccione et al.**\(^{34}\) [2011] | Prospective Multi-centre Observational (Canada) | Adalimumab [40] | NR | 46%\(^{\text{a}}\) | 53%\(^{\text{a}}\) | 22%\(^{\text{a}}\) |
| **Sandborn et al.**\(^{35}\) [2011] | Prospective Multi-centre Randomised control trial (International) | Adalimumab [71] | Median 148 days [range 106–338] | NR | 52% | NR |

\(^{\text{a}}\) values may vary depending on the study.
| Author (year)       | Study design (country)                        | Anti-TNF agent intensified (number intensified) | Anti-TNF duration prior to dose intensification | Immuno modulator co-therapy (%) | Prior biologic failure (%) | Perianal disease (%) |
|--------------------|-----------------------------------------------|------------------------------------------------|-----------------------------------------------|--------------------------------|--------------------------|----------------------|
| Löfberg et al.     | Prospective Multi-centre Observational (Europe)| Adalimumab [131]                                | Median 92 days (range 70–157)                  | 55%                           | 49%                      | 18%                  |
| Baert et al.       | Retrospective Multi-centre Observational (Belgium)| Adalimumab [208]                              | Median 7 months (range 0–55)                   | 38%                           | 64%                      | 42%                  |
| Ma et al.          | Retrospective Single-centre Observational (Canada)| Adalimumab [92]                                | Median 37 weeks (IQR 20–76)                   | 58%                           | 54%                      | 32%                  |
| Watanabe et al.    | Prospective Multi-centre Randomised control trial (Japan)| Adalimumab [40]                                 | NR                                             | 15%                           | 63%                      | NR                   |
| Bouguen et al.     | Retrospective Observational Multi-centre France | Adalimumab [42]                                | Median 1.3 years (IQR 75, 0.5–3)              | 10%                           | 79%                      | 50%                  |
| Duveau et al.      | Retrospective Single-centre Observational (Canada)| Adalimumab [124]                               | Median 10 months (range 4–27)                 | 20%                           | 55%                      | 47%                  |
| Motoya et al.      | Prospective Multi-centre Observational (Japan) | Adalimumab [28]                                 | NR                                             | 46%                           | 68%                      | NR                   |
| Restellini et al.  | Retrospective Single-centre Observational (Canada)| Adalimumab [48]                                | Median 22 months (range 6–36)                 | 38%                           | 44%                      | 31%                  |
| Verstockt et al.   | Retrospective Single-centre Observational (Belgium)| Adalimumab [43]                                 | NR                                             | 13%                           | 0%                       | 24%                  |
| Suzuki et al.      | Retrospective Multi-centre Observational (Japan) | Adalimumab [12]                                 | Median 19 months (range 3–149)                | 25%                           | 33%                      | 50%                  |
| Author (year)          | Study design (country)                      | Anti-TNF agent intensified (number intensified) | Anti-TNF duration prior to dose intensification | Immuno modulator co-therapy (%) | Prior biologic failure (%) | Perianal disease (%) |
|-----------------------|---------------------------------------------|------------------------------------------------|-----------------------------------------------|-------------------------------|---------------------------|---------------------|
| Both infliximab and adalimumab |                                             |                                                |                                               |                               |                           |                     |
| Ghaly et al. \(^{41}\) [2014] | Retrospective Multi-centre Observational [Australia] | Infliximab \(^{20}\) Adalimumab \(^{35}\) | NR                                            | NR                            | 42%                       | 29%                 |
| Viazis et al. \(^{42}\) [2015] | Prospective Multi-centre Observational [Greece] | Infliximab \(^{18}\) Adalimumab \(^{13}\) | Median 9 months [range 2–22] | 100% \(^{a}\) [at anti-TNF initiation] | No                         | 52%                 |
| Maria Del Carmen et al. \(^{45}\) [2016] | Retrospective Multi-centre Observational [Spain] | Infliximab \(^{24}\) | Mean 11.9 ± 10.9 months [range 1–40] | 46% \(^{a}\) | 100% | 45% \(^{a}\) |
| Narula et al. \(^{43}\) [2016] | Prospective Multi-centre Observational [Austria] | Infliximab \(^{5}\) Adalimumab \(^{14}\) | Median 6 months [infliximab] Median 5 months [adalimumab] | Infliximab 45% Adalimumab 37% | No | Infliximab 5% Adalimumab 0% |
| Preda et al. \(^{44}\) [2016] | Retrospective Multi-centre Observational [Romania] | Infliximab \(^{26}\) Adalimumab \(^{19}\) | Mean 15.5 months [infliximab] Mean 12.7 months [adalimumab] | 78% \(^{a}\) | No | NR |
| Srinivasan et al. \(^{7}\) [2018] | Retrospective Multi-centre Observational [Australia] | Infliximab \(^{22}\) Adalimumab \(^{11}\) | Median 1.8 years | 76% | 27% | 39% |
| | | Infliximab \(^{29}\) Adalimumab \(^{26}\) | Median 2.5 years | 89% | 38% | 45% |

NR, not reported; immunomodulator: thiopurine or methotrexate.

\(^{a}\)Across entire study, not just intensified subgroup.
Table 2. Tertiary response and remission following anti-TNF dose intensification.

| Author (year) | Anti-TNF dose intensification regimen (number intensified) | Criteria for dose intensification | Definition of tertiary response/remission following dose intensification | Tertiary response following dose intensification (timepoint) | Tertiary remission following dose intensification (timepoint) | Predictors of tertiary response/remission following dose intensification |
|---------------|----------------------------------------------------------|----------------------------------|---------------------------------------------------------------------|-----------------------------------------------------------|-------------------------------------------------------------|---------------------------------------------------------------|
| Rutgeerts et al. [25] (2004) | Infliximab 10 mg/kg, 8 weekly [58] | 70-point CDAI increase from baseline with total CDAI > 175 or increase in CDAI by 35% from baseline | Clinical response ≥ 70-point reduction in CDAI from baseline and ≥ 25% from baseline | 52/58 (90%) [short-term response] | NR | NR |
| Chaparro et al. [26] (2011) | Infliximab 10 mg/kg, 8 weekly [65]5 mg/kg, 4–7 weekly [62] | Impairment of symptoms coupled with clinical, endoscopic, radiographic and/or serologic (CRP) evidence of inflammation | Clinical response Decrease in HBI > 3 Clinical remission HBI ≤ 4 without corticosteroids | 51/127 (40%) [clinical response following first intensified infusion] | 71/127 (56%) [clinical remission following first intensified infusion] | NR |
| Hibi et al. [27] (2012) | Infliximab 5 mg/kg, 4 weekly [20] | 70-point CDAI increase from baseline with total CDAI > 175 or increase in CDAI by 35% from baseline | Clinical response ≥ 70-point reduction in CDAI from baseline or ≥ 25% from baseline Clinical remission CDAI ≤ 150 | 15/18 (83%) [54 weeks] | 10/18 [56%] [54 weeks] | NR |
| Kopylov et al. [28] (2011) | Infliximab [94] | Per treating physician’s judgement | Immediate response defined as symptom improvement at first clinic visit (4–8 weeks) after dose intensification as per treating physician judgement, coupled with decision to continue intensification without alteration. Sustained response was defined as improvement of symptoms lasting at least 1 year without further alterations in therapeutic regimen | 64/94 (68%) [immediate response within 2–8 weeks]27/76 (36%) [sustained response, ≥ 1 year] | NR | ↑ normalisation of CRP following dose intensification |

(continued)
| Author (year) | Anti-TNF dose intensification regimen [number intensified] | Criteria for dose intensification | Definition of tertiary response/remission following dose intensification | Tertiary response following dose intensification (timepoint) | Tertiary remission following dose intensification (timepoint) | Predictors of tertiary response/remission following dose intensification |
|--------------|----------------------------------------------------------|---------------------------------|----------------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------------------|
| Infliximab   | 10 mg/kg, 8 weekly [25]                                  | As above                        | As above                                                        | 13/25 [52%] [4 weeks]                                      | 7/25 [28%] [4 weeks]                                        |                                                                 |
| Infliximab   | 5 mg/kg, 4–7 weekly [7]                                  | As above                        | As above                                                        | 1/7 [15%] [4 weeks]                                        | 4/7 [57%] [4 weeks]                                        |                                                                 |
| Katz et al.  | Infliximab [168]                                        | Per treating physician's judgement | Immediate response defined as symptom improvement at first clinic visit [4–8 weeks] after dose intensification as per treating physician judgement, coupled with decision to continue intensification without alteration. Sustained response was defined as improvement of symptoms lasting at least 1 year without further alterations in therapeutic regimen | 123/168 [73%] [immediate response within 4–8 weeks] 78/166 [47%] [sustained response, ≥1-year] | NR                                                       | ↑ baseline CRP normal ↑ stricturing and penetrating phenotype ↑ non-smoking status ↑ age of diagnosis between 16–40 |
| Infliximab   | 10 mg/kg, 8 weekly [112]                                 | As above                        | As above                                                        | 8/112 [77%] [immediate response] 56/111 [50%] [sustained response, ≥1 year] | NR                                                       |                                                                 |
| Infliximab   | 5 mg/kg, 4 weekly [56]                                   | As above                        | As above                                                        | 37/56 [66%] [immediate response] 22/55 [39%] [sustained response, ≥1 year] | NR                                                       |                                                                 |
| Lin et al.   | Infliximab [30]                                         | Per treating physician’s judgement based on disease-related symptoms in the context of objective data including inflammatory markers, endoscopic activity and radiologic imaging | Clinical response Symptomatic improvement with ongoing dose intensified infliximab for ≥3 infusions | 24/30 [80%] [after 3 intensified infliximab infusions] 10/30 [33%] [sustained, ≥1 year] | NR                                                       | None                                                            |
| Infliximab, 10 mg/kg, 8 weekly [17] | As above                                                  | As above                        | As above                                                        | 13/17 [76%] [after 3 intensified infusions] 7/17 [41%] [sustained, ≥1 year] | NR                                                       |                                                                 |
| Infliximab, 5 mg/kg, 4–6 weekly [8] | As above                                                  | As above                        | As above                                                        | 7/8 [88%] [after 3 intensified infusions] 1/8 [13%] [sustained, ≥1 year] | NR                                                       |                                                                 |
| Author (year) | Anti-TNF dose intensification regimen (number intensified) | Criteria for dose intensification | Definition of tertiary response/remission following dose intensification | Tertiary response following dose intensification (timepoint) | Tertiary remission following dose intensification (timepoint) | Predictors of tertiary response/remission following dose intensification |
|--------------|----------------------------------------------------------|---------------------------------|-------------------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
| Steenholdt et al. [15] (2014) | Infliximab 10 mg/kg, 4–6 weekly [5] | As above | Clinical response >70-point reduction in CDAI from baseline, or ≥50% reduction active fistulas Clinical remission CDAI ≤ 150 and complete closure of all fistulas despite gentle pressure | 4/5 (80%) [after 3 intensified infusions] 2/5 (40%) [sustained, ≥1 year] | NR |  |
| Steenholdt et al. [29] (2015) | Infliximab 5 mg/kg, 4 weekly [36] | CDAI ≥ 220 and/or ≥1 draining perianal fistula | Clinical response >70-point reduction in CDAI from baseline, or ≥50% reduction active fistulas Clinical remission CDAI ≤ 150 and complete closure of all fistulas despite gentle pressure | 19/36 (53%) [12 weeks] | 14/36 (39%) [12 weeks] | NR |
| Suzuki et al. [16] (2015) | Infliximab 10 mg/kg, 8 weekly [39] | CDAI ≥ 175 at 8-weeks or CDAI ≥ 50 points from 4-weeks | Clinical response Reduction in median CDAI of ≥50 points in 8-weeks Clinical remission CDAI ≤ 150 | 26/39 (67%) [4 weeks] 23/39 (59%) [8 weeks] | 13/39 (39%) [8 weeks] 16/39 (41%) [40 weeks] | ↑ baseline serum infliximab trough level ≥1 mg/mL ↑ baseline plasma IL-6 levels <2.41 pg/mL ↑ baseline serum albumin level ≥ 3.8 g/dL |
| Nagata et al. [20] (2015) | Infliximab [26] | Deterioration in CDAI and CRP within an 8-week interval after administration of 5 mg/kg, 8 weekly infliximab | Clinical response >25% or 70-point reduction in CDAI Clinical remission CDAI < 150 | 18/26 (69%) [week 4] | 15/26 (58%) [week 4] 11/22 (50%) [week 48] | NR |
| Dreesen et al. [19] (2018) | Infliximab [103] | No longer being in remission based on physicians’ global assessment of signs and symptoms | Clinical response Marked decrease or disappearance of symptoms [physicians’ global assessment] | 65/103 (63%) [second infusion] 51/103 (50%) [1-year persistence] | NR | Biologic response ↑ magnitude of increase in adalimumab trough concentration following dose intensification ↑ achieving therapeutic trough concentrations |
| Author (year) | Anti-TNF dose intensification regimen (number intensified) | Criteria for dose intensification | Definition of tertiary response/remission following dose intensification | Tertiary response following dose intensification (timepoint) | Tertiary remission following dose intensification (timepoint) | Predictors of tertiary response/remission following dose intensification |
|---------------|----------------------------------------------------------|---------------------------------|-------------------------------------------------|---------------------------------------------------------|--------------------------------------------------------|---------------------------------------------------------------|
|               |                                                          |                                 | Tertiary response following dose intensification (timepoint) | Tertiary remission following dose intensification (timepoint) | Predictors of tertiary response/remission following dose intensification |
| Infliximab 10 mg/kg, 8 weekly [45] | As above | As above | 24/45 [53%] [second infusion] 21/45 [47%] [1-year persistence] | NR | | |
| 5 mg/kg dose interval shortened [45] | As above | As above | 33/45 [73%] [second infusion] 23/45 [51%] [1-year persistence] | NR | | |
| 10 mg/kg dose interval shortened [13] | As above | As above | 8/13 [62%] [second infusion] 7/13 [54%] [1-year persistence] | NR | | |
| Hendler et al. [30] (2015) | Infliximab >10 mg/kg, 8 weekly [86] | Treating physician’s clinical judgement | Clinical response Incomplete resolution of symptoms Clinical remission Complete resolution of symptoms | 31/66 [47%] [within 16 weeks] 21/61 [34%] [within 100 weeks] | 17/66 [25%] [within 16 weeks] 17/61 [28%] [within 100 weeks] | NR |
| Colombel et al. [31] (2009) | Adalimumab 40 mg weekly [40] | Disease Flare: increase in CDAI of ⩾70 points vs. week 4 and an absolute CDAI score >220 | Clinical response Decrease in CDAI of ⩾70 points | 34/40 [85%] [56 weeks] | NR | NR |
| Karmiris et al. [32] (2009) | Adalimumab 40 mg, weekly [70] | Recurrent symptoms of active luminal disease and were accompanied by an increase in CRP or endoscopic lesions | Clinical response Lasting control of disease activity by end of follow-up | 53/70 [78%] [long-term] | NR | ↑ adalimumab trough concentration post dose intensification |
| Baert et al. [6] (2013) | Adalimumab 40 mg, weekly [208] | Reappearance of symptoms and CRP re-elevation (if applicable) judged by treating investigator | Clinical response durable response for ⩾6 months or successful de-escalation within 6 months | 139/208 [67%] [6 months] | NR | NR |
| Ma et al. [23] (2014) | Adalimumab 40 mg, weekly or 80 mg, 2 weekly [92] | HBI >5 AND ⩾3 points from post-induction baseline AND elevated inflammatory markers [CRP > 10, FCP > 50] or evidence of activity on endoscopy or CT enterography | Clinical response Decrease in HBI of ⩾3 points | 74/92 [80%] [within 24 weeks] | NR | NR |

Table 2. (Continued)
| Author (year) | Anti-TNF dose intensification regimen (number intensified) | Criteria for dose intensification | Definition of tertiary response/remission following dose intensification | Tertiary response following dose intensification (timepoint) | Tertiary remission following dose intensification (timepoint) | Predictors of tertiary response/remission following dose intensification |
|--------------|---------------------------------------------------------|----------------------------------|---------------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|---------------------------------------------------------------|
| Bouguen et al. [2015] | Adalimumab 80 mg, 2 weekly [42] | CDAI > 150 and 1 objective sign of inflammation (elevated C-reactive protein, CRP > 5 mg/L and/or faecal calprotectin > 300 ug/g and/or radiologic and/or endoscopic evidence of disease activity), | Clinical response: 70 point decrease in CDAI from baseline Clinical remission: CDAI < 150 without steroids | 23/42 [55%] [short-term, median 4.9 weeks] | 14/42 [33%] [short-term median 4.9 weeks] | Baseline CDAI < 260 |
| Duveau et al. [2017] | Adalimumab 40 mg, weekly [100], 80 mg, 2 weekly [24] | Physician-determined increase in clinical Crohn’s disease activity | Clinical response: Significant improvement in Crohn’s disease-related clinical symptoms and laboratory tests assessed by treating physician, leading to continued adalimumab treatment, associated with complete weaning from steroids, without luminal or anal surgery, or introduction of immunosuppressants | 99/124 [79%] [3 months] | 62/124 [58%] [12 months] | ↑ secondary loss of response ≥10 months after adalimumab initiation ↑ stricture phenotype ↑ adalimumab 40 mg weekly vs adalimumab 80 mg 2 weekly ↑ baseline CRP ≤ 5 mg/L |
| Motoya et al. [2017] | Adalimumab 80 mg, 2 weekly [28] | CDAI ≥ 200 including CDAI ≥ 50 points from lowest CDAI AND CRP ≥ 1 mg/dL | Clinical response: Reduction in CDAI of ≥50 points in 8 weeks Clinical remission: CDAI < 150 | 21/28 [75%] [8 weeks] | 7/28 [25%] [8 weeks] | ↑ lower baseline CDAI ↑ lower week-4 CDAI |
| Restellini et al. [2018] | Adalimumab 40 mg, weekly [48] | HBI > 5 and/or biochemical evidence of disease (CRP/ faecal calprotectin) and/or endoscopic findings confirming active disease in patients who were in remission before | Clinical remission: HBI < 5, with CRP < 5 mg/L, faecal calprotectin < 250 ug/g, and SES-CD score < 3 | NR | 4/25 [16%] [3 months] | NR |

(continued)
### Table 2. (Continued)

| Author (year) | Anti-TNF dose intensification regimen (number intensified) | Criteria for dose intensification | Definition of tertiary response/remission following dose intensification | Tertiary response following dose intensification (timepoint) | Tertiary remission following dose intensification (timepoint) | Predictors of tertiary response/remission following dose intensification |
|---------------|----------------------------------------------------------|----------------------------------|-----------------------------------------------------------------------|------------------------------------------------------------|--------------------------------------------------------------|---------------------------------------------------------------|
| **Suzuki et al.**<sup>22</sup> (2019) | Adalimumab 80 mg, 2 weekly (12) | CDAI $\geq 150$ or elevated CRP | Clinical response $\geq$-70-point reduction Clinical remission CDAI $< 150$-points | 4/12 [33%] | 8/12 [67%] | NR |
| **Adalimumab dose intensification: primary non-response or secondary loss of response** | | | | | | |
| **Bultman et al.**<sup>23</sup> (2012) | Adalimumab 40 mg, weekly (46) | Physician determined need to decrease the dosing interval in patients that failed to respond or lost response, where loss of response was defined as increase in CDAI $> 50$ points from baseline | Clinical response Treating physician-determined response | 20/46 [43%]<sup>a</sup> [3 months] | NR | NR |
| **Panaccione et al.**<sup>24</sup> (2011) | Adalimumab 40 mg, weekly (120) | Physician-determined flare or non-response | Clinical response Decrease in HBI by $\geq 3$ from baseline Clinical remission HBI $< 4$ | 85/120 [71%]<sup>b</sup> [24 weeks] | 36/120 [30%]<sup>b</sup> [24 weeks] | NR |
| **Sandborn et al.**<sup>25</sup> (2011) | Adalimumab 40 mg, weekly (71) | Not achieving CDAI reduction of $\geq 70$ points from baseline | Clinical response Reduction in CDAI $> 70$-points [CR-70] Clinical remission CDAI $< 150$ | 45/71 [63%]<sup>a</sup> [CR-70, within 56 weeks] | 26/71 [37%]<sup>a</sup> (within 56 weeks) | NR |
| **Löfberg et al.**<sup>26</sup> (2012) | Adalimumab 40 mg, weekly (131) | Disease flare characterised by increase in HBI $\geq 3$ and total HBI $\geq 7$; OR Non-response defined as drop in HBI $< 3$ from baseline | Clinical response Decrease in HBI by $\geq 3$ Clinical remission HBI $< 5$ | 76/131 [58%]<sup>a</sup> [20 weeks] | 46/131 [35%]<sup>a</sup> [20 weeks] | NR |
| **Watanabe et al.**<sup>27</sup> (2014) | Adalimumab 80 mg, 2 weekly (40) | Flare defined as recurrence of active disease i.e. CDAI $> 220$ including an increase of $>70$ points from baseline | Clinical response Decrease in CDAI by $\geq 70$-points from baseline Clinical remission CDAI $< 150$ | 8/40 [20%]<sup>a</sup> [48 weeks] | 6/40 [15%]<sup>a</sup> [48 weeks] | NR |
| **Verstockt et al.**<sup>28</sup> (2018) | Adalimumab 40 mg, weekly (43) | Physician initiated dose intensification $\geq 4$ weeks following adalimumab initiation | Clinical response Global physician assessment | 31/43 [72%]<sup>a</sup> [median 88.7 weeks] | NR | NR |
| Author (year) | Anti-TNF dose intensification regimen (number intensified) | Criteria for dose intensification | Definition of tertiary response/remission following dose intensification | Tertiary response following dose intensification (timepoint) | Tertiary remission following dose intensification (timepoint) | Predictors of tertiary response/remission following dose intensification |
|--------------|---------------------------------------------------------|----------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Viazis et al. (2015) | Infliximab 10 mg/kg, 4–8 weekly [18] Adalimumab 40 mg, weekly [13] | Recurrence of clinical symptoms with elevated CRP or endoscopic activity in patients that initially responded to anti-TNF | Clinical remission Absence of symptoms and normal CRP | NR | 25/31 [81%] [≥ 12 months] | NR |
| Maria Del Carmen et al. (2016) | Infliximab Dose increase and/or dose interval shortening Adalimumab 40 mg, weekly [24] | Worsening of symptoms associated with endoscopic, radiographic and/or serological evidence of inflammation | Clinical response Decrease in HBI by ≥3 from baseline; OR >50% reduction in draining fistulas Clinical remission HBI = 4 without steroids; OR Closure of all fistulas | 11/24 [46%] [short-term follow-up] | 8/24 [33%] [short-term follow-up] | NR |
| Narula et al. (2016) | Infliximab [22] Adalimumab [14] | Physician-determined flare following primary response to anti-TNF therapy | Clinical response Decrease in HBI by ≥3 from baseline; OR >50% reduction in baseline number of draining fistula Clinical remission HBI < 5; OR Complete cessation of drainage from perianal fistulas | 6/21 [29%] [12 months] | 9/21 [43%] [12 months] | NR |
| Preda et al. (2016) | Infliximab 10 mg/kg, 8 weekly [17] 5 mg/kg, 4–7 weekly [5] | As above | As above | Infliximab 4/16 [25%] [12 months] | Infliximab 8/16 [50%] [12 months] | |
| | Adalimumab 40 mg, weekly [14] | As above | As above | Adalimumab 2/5 [40%] [12 months] | Adalimumab 1/5 [20%] [12 months] | |
| | Infliximab [26] Adalimumab [19] | Physician-determined clinical loss of response | Clinical response Decrease in CDAI by >70 points Clinical remission CDAI < 150 at last evaluation | NR | NR | NR |
| | Infliximab 10 mg/kg, 8 weekly [13] 5 mg/kg, 4–7 weekly [13] | As above | As above | Infliximab 11/26 [42%] [after mean 36 months] | | |
| Author (year)                  | Anti-TNF dose intensification regimen (number intensified) | Criteria for dose intensification                                                                 | Definition of tertiary response/remission following dose intensification | Tertiary response following dose intensification (timepoint) | Tertiary remission following dose intensification (timepoint) | Predictors of tertiary response/remission following dose intensification |
|-------------------------------|----------------------------------------------------------|-------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-------------------------------------------------------------------------|
| Adalimumab 40 mg, weekly [19] | As above                                                 | As above                                                                                       | Adalimumab 16/19 [84%] (after mean 20 months)                         |                                                                 |                                                                 |                                                                 |
| Infliximab [51] Adalimumab [37]| HBI $\geq$ 5 and objective evidence of disease [CRP $\geq$ 5 mg/L, FCP $\geq$ 100 ug/mL] | Clinical remission HBI $<$ 5                                                                 | NR                                                                     | 36/59 [61%] (last clinical review)                                | NR                                                              |                                                                 |
| Infliximab 5 mg/kg, 0, 2, 6 re-induction [22]| As above                                                   | As Above                                                                                       | NR                                                                     | 11/17 [65%] (last clinical review, median 3.5 years)              |                                                                 |                                                                 |
| Adalimumab 160 mg/80 mg, 0, 2 re-induction [11] | As above                                                 | As above                                                                                       | NR                                                                     | 25/42 [60%] (last clinical review, median 1.5 years)              |                                                                 |                                                                 |
| Both infliximab and adalimumab dose intensification: primary non-response or secondary loss of response |                                                                                                       |                                                                                                    |                                                                 |                                                                 |                                                                 |                                                                 |
| Ghaly et al. [41] (2014)      | Infliximab 5 mg/kg, 0, 2, 6 re-induction [8] Infliximab 5 or 10 mg/kg, 6 weekly [11] Adalimumab 40 mg, weekly [35] | Clinically active Crohn’s disease supported by laboratory parameter, imaging or endoscopy       | Good response physician and patient satisfied by clinical response Partial response guarded comments regarding clinical response | 50/55 [91%] any response, 3 months$^a$ 40/55 [73%] good response, 3 months$^a$ 10/55 [18%] partial response, 3 months$^a$ | NR                                                              | $\uparrow$ absence of continuous corticosteroids for $\geq$ 6 months in preceding 5 years |

CDAI, Crohn’s disease activity index; CRP, C-reactive protein; HBI, Harvey-Bradshaw Index; NR, not reported.

$^a$Pooled outcomes following anti-TNF dose intensification for primary non-response and secondary loss of response.
were evaluated across 19 studies, 13 of which evaluated outcomes following infliximab dose intensification alone, with the remaining six studies evaluating outcomes across mixed adalimumab and infliximab cohorts.

**Clinical outcomes following infliximab dose intensification.** Clinical response and remission across all infliximab dose-intensification studies, strategies and timepoints ranged from 25% to 90% and 19% to 58%, respectively. Short- to medium-term clinical response following infliximab dose intensification undertaken to address secondary LOR using any dose-intensification strategy ranged from 40% to 90% at 4–8 weeks to 28–80% at 12–24 weeks; with longer-term response after at least 1 year sustained in 25–83% of patients.\(^4,5,15,16,19–21,25–29,43\) The proportion of patients who achieved short-term clinical remission using any infliximab dose-intensification strategy to address secondary LOR at 4–12 weeks was 19–58%, while long-term clinical remission was reported in 41–56%.\(^15,16,20,26–29,43,44\) Only one study adopted infliximab dose intensification to address both non-response and secondary LOR, and despite the use of high-dose infliximab intensification (\(\geq 10 \text{ mg/kg 4–7 weekly}\)), reported short-term and sustained clinical response in 47% and 34% of patients, respectively.\(^30\)

**Infliximab 10 mg/kg 8 weekly.** Eleven studies included patients who underwent infliximab 10 mg/kg 8 weekly dose intensification, of which seven studies reported clinical response and three studies reported clinical remission outcomes specific to this dosing strategy. Seven studies reported short-term clinical response in 52–90% of patients within 12 weeks.\(^5,16,19–21,25,28\) Three studies reported sustained clinical response in 13–51% of patients following at least 12 months of intensification.\(^5,19,21\) Two studies reported clinical remission in 28–54% of patients after 12-weeks of intensification.\(^15,29\) Only one study reported sustained clinical remission following 48 weeks of intensification in 54% of patients.\(^20\)

**Infliximab 5 mg/kg 4–7 weekly.** Six studies included patients who underwent infliximab 5 mg/kg 4 weekly dose intensification, of which five studies reported clinical response and two studies reported clinical remission outcomes specific to these dose-intensification strategies. Five studies reported clinical response in 15–88% of patients within 18 weeks of intensification.\(^4,19–21,28\) Three studies reported sustained clinical response in 13–51% of patients following at least 12 months of intensification.\(^4,19,21\) Two studies reported clinical remission in 57–62% of patients 4 weeks following intensification.\(^20,28\) Only one study reported sustained clinical remission following 48 weeks of intensification in 54% of patients.\(^20\)

**Factors associated with response and/or remission following infliximab dose-intensification.** Several factors have been associated with favourable clinical outcomes following infliximab dose intensification. Katz *et al.*\(^5\) found that immediate clinical response was associated with a stricturing (OR 4.1, 95% CI (1.8–9.1)) or penetrating (OR 4.1 (1.8–9.1)) phenotype and normal baseline CRP (OR 3.2, (1.2–9.4)) *via* multivariate analysis. Similarly, Kopylov *et al.*\(^4\) reported that normalisation of CRP following infliximab dose intensification was associated with immediate clinical response (OR 4.2 (1.2–15.2)), relative to persistent CRP elevation.
Katz et al.\textsuperscript{5} also documented that sustained response at 1 year was associated with younger age (16–40 years) at disease diagnosis (OR 2.7 (1.1–7.7)), and normal CRP (OR 4.0 (1.5–10.3)) at LOR. The proportion of patients achieving clinical remission at week 40 was found to be higher in patients with serum infliximab trough levels $\geq 1$ mg/mL, plasma interleukin (IL)-6 levels $\leq 2.41$ pg/mL and/or serum albumin level $\geq 3.8$ g/dL at baseline by Suzuki et al.\textsuperscript{16} Dreesen et al. also noted that patients who achieved biologic response (defined by reduction in CRP by 50% or CRP $\leq 5$ mg/L from baseline CRP $> 5$ mg/L) and remission (CRP $\leq 5$ mg/L from baseline CRP $> 5$ mg/L) following infliximab dose intensification were more likely to have higher infliximab trough levels.\textsuperscript{19} Moreover, a therapeutic ($> 3.0$ ug/mL) infliximab trough concentration was also positively associated with biologic response.\textsuperscript{19}

**Adalimumab dose intensification**

Adalimumab dose intensification was undertaken exclusively for secondary LOR in 14 of 21 studies. Unlike infliximab, the majority ($n=17$) of adalimumab studies included patients who were anti-TNF naïve. Adalimumab dose-intensification strategies evaluated included adalimumab 40 mg weekly ($n=17$), adalimumab 80 mg 2 weekly ($n=6$), and adalimumab re-induction ($n=1$).\textsuperscript{6,7,17,22–24,31–45} These regimens were evaluated in 21 studies, 15 of which evaluated outcomes following adalimumab dose intensification alone, with the remaining six studies evaluating outcomes across mixed adalimumab and infliximab cohorts.

**Clinical outcomes following adalimumab dose intensification.** Clinical response and remission across all adalimumab dose-intensification studies, strategies, and timepoints ranged from 20% to 85% and 15% to 84%, respectively. Short-term clinical response within 12 weeks of adalimumab dose intensification undertaken to address secondary LOR across all dose-intensification strategies ranged from 33% to 79%, while clinical response within 24 weeks ranged from 29% to 80%, and sustained clinical response following at least 1 year of intensified adalimumab therapy ranged from 33% to 85%.\textsuperscript{6,17,22–24,31,32,38,43} Short-term clinical remission following adalimumab dose intensification to address secondary LOR was achieved at 8–12 weeks in 16–67% of patients, while medium-term (12–24 weeks) and sustained ($\geq 52$ weeks) clinical remission was reported in 24–43% and 20–84% of patients, respectively.\textsuperscript{17,22,38,39,43,44}

Comparatively, six studies used adalimumab dose intensification to address both non-response and secondary LOR, with overall adalimumab response ranging from 20% to 72%.\textsuperscript{31,33–37,40} Of these six studies, three reported short-term ($\leq 24$ weeks) response in 58–72% of patients, while three studies reported sustained response ($\geq 52$ weeks) in 20–72% of patients.\textsuperscript{33–37,40}

**Adalimumab 40 mg weekly.** Seventeen studies included patients who underwent adalimumab 40 mg weekly dose intensification, of which nine studies reported clinical response and six studies reported clinical remission outcomes specific to this dose-intensification strategy. Four studies reported clinical response in 35–71% of patients following 3–6 months of intensification.\textsuperscript{5,33,34,36} Five studies reported sustained clinical remission in 40–85% of patients following at least 12 months of intensification.\textsuperscript{31,32,35,40,43} Three studies reported clinical remission in 16–35% of patients following 3–6 months of intensification.\textsuperscript{34,36,39} Three studies reported sustained clinical remission following at least 12 months of intensification in 20–84% of patients.\textsuperscript{35,43,44}

**Adalimumab 80 mg 2 weekly.** Six studies included patients who underwent adalimumab 80 mg 2 weekly dose intensification, of which four studies reported clinical response and four studies reported clinical remission outcomes specific to this dose-intensification strategy. Three studies reported short- to medium-term clinical response in 39–75% of patients within 6 months of intensification.\textsuperscript{17,22,38} Three studies also reported sustained clinical response in 20–57% of patients following at least 12 months of intensification.\textsuperscript{16,17,37} Similarly, three studies reported clinical remission in 24–67% of patients within 6-months of intensification and sustained clinical remission following at least 48-weeks of intensification in 15–50% of patients.\textsuperscript{17,22,37}

**Adalimumab 40 mg weekly or adalimumab 80 mg 2 weekly.** Two studies reported pooled outcomes following adalimumab 40 mg weekly and 80 mg 2 weekly. Short-term clinical response was achieved in 79–80% of intensified patients between 3 and 6 months, while sustained clinical response at 12 months was achieved in 60%.\textsuperscript{23,24}
Factors associated with response and/or remission following adalimumab dose intensification. Duveau et al.\textsuperscript{24} found that adalimumab 40 mg weekly rather than 80 mg 2 weekly (OR 3.6, 95% CI (1.3–10.4)) and CRP $\leq 5$ mg/L at dose intensification (OR 6.6 (1.4–27.5)) were associated with 12 month clinical response to adalimumab dose intensification. Secondary LOR that developed 10 months or more (OR 2.6 (1.0–6.5)) after adalimumab initiation and strictureing disease (OR 4.4 (1.4–14.0)) were also found to be associated with clinical response at 3 months.\textsuperscript{24} Motoya et al.\textsuperscript{17} also noted that CDAI at baseline and at 4 weeks were each lower in patients that achieved 24-week clinical remission.

Pooled infliximab and adalimumab dose intensification
Clinical outcomes following pooled infliximab and adalimumab dose intensification. Six studies reported outcomes across cohorts that underwent both infliximab and adalimumab dose intensification, including two studies that reported outcomes across infliximab and adalimumab subgroups.\textsuperscript{7,41–45} The remaining four studies only reported pooled outcomes following infliximab and adalimumab dose intensification, including one study by Ghaly et al.\textsuperscript{41} which included patients that underwent dose intensification for primary non-response.\textsuperscript{7,41,42,45} Pooled outcomes across these four studies using any infliximab or adalimumab dose-intensification strategy, reported clinical response in 46–91% (\(\leq 3\) months) and sustained clinical remission in 61–81% of patients.\textsuperscript{7,41,42,45}

Factors associated with response and/or remission following pooled infliximab and adalimumab dose intensification. Ghaly et al.\textsuperscript{41} reported that the absence of continuous corticosteroids for $\geq 6$ months in the 5 years preceding anti-TNF dose intensification was the sole predictor of durable steroid-free remission over the 12 months following dose intensification (OR 3.5, 95% CI 1.05–12.05).

Non-response and LOR following anti-TNF dose intensification
Nineteen studies reported or allowed imputa- tion of clinical outcomes pertaining to tertiary non-response and tertiary LOR following infliximab and/or adalimumab dose intensification (Table 3).\textsuperscript{4,7,16,17,21,23–25,28–30,33,35,38,41,44,45}

Tertiary non-response. Tertiary non-response within 6 months of anti-TNF dose intensification undertaken to address secondary LOR was reported in 10–45% of patients across 10 studies, including two studies that reported outcomes following both infliximab and adalimumab dose intensification.\textsuperscript{6,16,17,21,24,28,29,38,44,45} When outcomes were analysed by anti-TNF agent, tertiary non-response occurred in 10–58% and 14–45% of patients following infliximab and adalimumab dose intensification, respectively. Comparatively, three studies included patients who underwent anti-TNF dose intensification for both primary non-response and secondary LOR, reporting tertiary non-response in 7–37% of patients.\textsuperscript{30,33,41}

Tertiary LOR. Tertiary LOR following at least 6 months of anti-TNF dose intensification to address secondary LOR was reported in 7–64% of patients across 10 studies; including 16–64% and 7–57% of patients following infliximab and adalimumab dose intensification, respectively.\textsuperscript{4,5,7,16,17,21,23–25,28} Comparatively, two studies included patients who underwent anti-TNF dose intensification for both primary non-response and secondary LOR, reporting tertiary LOR in 30–38% of patients.\textsuperscript{30,35}

Predictors of tertiary non-response and tertiary LOR following anti-TNF dose intensification. Baert et al.\textsuperscript{6} reported that failure of dose intensification was associated with elevated CRP at baseline, while Ma et al.\textsuperscript{23} ascribed the need for concurrent corticosteroid therapy at initial adalimumab induction to a reduced likelihood of response to adalimumab dose intensification following secondary LOR. Duveau et al.\textsuperscript{24} reported that tertiary LOR occurred less frequently over time with adalimumab 40 mg weekly than 80 mg 2-weekly and with a CRP $\leq 5$ mg/L compared with a CRP $> 5$ mg/L prior to dose intensification. Ma et al. also reported that factors including CRP $> 10$ mg/L and prior anti-TNF exposure were associated with an increased risk of tertiary LOR on univariate analysis, while elevated CRP was predictive of shorter time to tertiary LOR on Kaplan–Meier analysis\textsuperscript{23}. In a pooled cohort who underwent anti-TNF re-induction and/or dose interval shortening with infliximab and adalimumab, longer time to treatment failure was associated with higher baseline serum albumin, male sex, and thiopurine co-therapy on multiple regression analyses.\textsuperscript{7}
### Table 3. Tertiary non-response and loss of response following anti-TNF dose intensification.

| Author (year) | Anti-TNF dose intensification regimen (number intensified) | Definition of tertiary non-response/loss of response following dose intensification | Tertiary non-response following dose intensification (timepoint) | Tertiary loss of response following dose intensification (timepoint) | Predictors of tertiary non-response/loss of response following dose intensification |
|---------------|----------------------------------------------------------|----------------------------------------------------------------------------------|-----------------------------------------------------------------|----------------------------------------------------------------|---------------------------------------------------------------------------------|
| Rutgeerts et al.²⁵ (2004) | Infliximab (58) | Discontinuation of intensified infliximab due to lack of efficacy | NR | 9/58 [16%] within 54 weeks | NR |
| Kopylov et al.² (2011) | Infliximab (94) | Absence of symptomatic improvement and a decision to further dose increase or dose interval shorten, add immunomodulator or corticosteroids, switch anti-TNF medications or Crohn’s disease-related surgery | NR | 49/76 [64%] 1 year | NR |
| Chaparro et al.²⁸ (2012) | Infliximab (33) | Loss of response following infliximab dose intensification | 7/33 [21%] 4 weeks | 13/26 [50%] median 33 months | NR |
| Katz et al.³ (2012) | Infliximab (168) | Absence of symptomatic improvement and a decision to further dose increase or dose interval shorten, add immunomodulator or corticosteroids, switch anti-TNF medications or Crohn’s disease-related surgery | NR | 88/166 [53%] 1 year | NR |
| Lin et al.²¹ (2012) | Infliximab (30) | Tertiary non-response to initial dose intensification, and tertiary loss of response following initial response to dose intensification, were defined as persistent disease-related symptoms followed by [1] resumption of steroids, [2] Crohn’s disease-related hospitalisation or surgery, or [3] discontinuation of infliximab in favour of another biologic | 6/30 [20%] after three intensified infusions | 14/30 [47%] median 9 months | NR |
| Steenholdt et al.²³ (2015) | Infliximab (36) | Lack of effect to 4-weekly infliximab dose intensification | 12/36 [33%] 20 weeks | NR | NR |
| Suzuki et al.²⁶ (2015) | Infliximab (39) | Discontinuation attributable to lack of efficacy to intensified dosing | 4/39 [10%] 8 weeks | 7/39 [18%] 40 weeks | NR |

**Infliximab dose intensification: primary non-response and secondary loss of response**

| Author (year) | Anti-TNF dose intensification regimen (number intensified) | Definition of tertiary non-response/loss of response following dose intensification | Tertiary non-response following dose intensification (timepoint) | Tertiary loss of response following dose intensification (timepoint) | Predictors of tertiary non-response/loss of response following dose intensification |
|---------------|----------------------------------------------------------|----------------------------------------------------------------------------------|-----------------------------------------------------------------|----------------------------------------------------------------|---------------------------------------------------------------------------------|
| Hendler et al.³⁰ (2015) | Infliximab (86) | Lack of improvement in symptoms | 10/66 [15%] within 16 weeks | 23/61 [38%] within 100 weeks | NR |

**Adalimumab dose intensification: secondary loss of response**

| Author (year) | Anti-TNF dose intensification regimen (number intensified) | Definition of tertiary non-response/loss of response following dose intensification | Tertiary non-response following dose intensification (timepoint) | Tertiary loss of response following dose intensification (timepoint) | Predictors of tertiary non-response/loss of response following dose intensification |
|---------------|----------------------------------------------------------|----------------------------------------------------------------------------------|-----------------------------------------------------------------|----------------------------------------------------------------|---------------------------------------------------------------------------------|
| Baert et al.⁴ (2013) | Adalimumab (208) | Did not re-induce clinical response for at least 6-months | 49/208 [24%] 6 months | NR | ↑ baseline CRP elevated |
| Author (year) | Anti-TNF dose intensification regimen (number intensified) | Definition of tertiary non-response/loss of response following dose intensification | Tertiary non-response following dose intensification (timepoint) | Tertiary loss of response following dose intensification (timepoint) | Predictors of tertiary non-response/loss of response following dose intensification |
|--------------|----------------------------------------------------------|-----------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|
| Ma et al. [23] (2014) | Adalimumab [92] | HBI > 5 and >3 points from post-induction baseline AND elevated inflammatory markers [CRP > 10, faecal calprotectin > 50] or evidence of activity on endoscopy or CT enterography following initial response to adalimumab dose intensification | NR | 42/74 [57%] [median 48 weeks] | ↑ baseline CRP > 10.0 mg/L ↑ prior anti-TNF exposure ↑ need for corticosteroid therapy at initial adalimumab induction |
| Bouguen et al. [38] (2015) | Adalimumab [42] | did not achieve a 70 point drop in CDAI | 19/42 [45%] [<14 weeks] | NR | NR |
| Motoya et al. [17] (2017) | Adalimumab [28] | Did not achieve a ≥50 point reduction in CDAI at week 8, or across two consecutive CDAI evaluations after week 8 | 4/28 [14%] [8 weeks] | 2/28 [7%] [52 weeks] | NR |
| Duveau et al. [34] (2017) | Adalimumab [124] | Adalimumab discontinuation, or introduction/continuation of corticosteroids, or luminal or anal surgery, or introduction of immunomodulators | 21%, [3 months] 29%, [6 months] | 40%, [12 months] | ↓ adalimumab 40 mg weekly vs 80 mg 2-weekly ↑ baseline CRP > 5 mg/L |
| Sandborn et al. [35] (2011) | Adalimumab [71] | Discontinuation attributable to lack of efficacy to intensified dosing | NR | 21/71 [30%] [<=56 weeks] | NR |
| Bultman et al. [31] (2012) | Adalimumab [46] | Treating physician determined that dose intensification was not effective | 17/46 [37%] [3 months] | NR | NR |
| Both infliximab and adalimumab dose intensification: secondary loss of response | | | | | |
| María Del Carmen et al. [45] (2016) | Infliximab Adalimumab [24] | Did not achieve drop in HBI by ≥3; OR Did not achieve closure of at least 50% fistulas | 5/24 [21%] [short-term follow-up] | NR | NR |
| Preda et al. [44] (2016) | Infliximab [26] Adalimumab [19] | No response Drop in CDAI < 70 points | Infliximab 15/26 [58%] [short-term follow-up] Adalimumab 3/19 [16%] [short-term follow-up] | NR | NR |
Table 3. (Continued)

| Author (year) | Anti-TNF dose intensification regimen (number intensified) | Definition of tertiary non-response/loss of response following dose intensification | Tertiary loss of response following dose intensification (timepoint) | Tertiary non-response following dose intensification (timepoint) | Predictors of tertiary non-response/loss of response following dose intensification |
|---------------|----------------------------------------------------------|----------------------------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|----------------------------------------------------------------------------------|
| Srinivasan et al. (2018) | Infliximab (51) Adalimumab (37) | Treatment failure refers to any of: (1) Crohn’s disease-related abdominal surgery, (2) anti-TNF cessation, or (3) switching to another biologic agent | NR | NR | ↓ baseline thiopurine co-therapy ↓ higher baseline serum albumin ↓ male sex |
| Ghaly et al. (2014) | Infliximab (35) Adalimumab (35) | Crohn’s disease activity index (HBI) Harvey–Bradshaw Index | NR | NR | Both infliximab and adalimumab dose intensification; primary non-response and secondary loss of response | 4/55 [7%] [3 months] |

**Meta-analysis**

**Differentiating between effective and ineffective dose intensification**

Studies evaluated as part of each meta-analysis below, that is, (1) tertiary response *versus* tertiary non-response and (2) tertiary response *versus* tertiary LOR, were assessed across comparable timepoints.

**Evaluating tertiary response and tertiary non-response.** Twelve studies reported both tertiary response and tertiary non-response within 6 months of infliximab (n = 5), adalimumab (n = 5) or co-reported infliximab/adalimumab (n = 2) dose intensification, including nine studies that used dose intensification to address secondary LOR alone. Clinical assessment of tertiary response and tertiary non-response was undertaken after a median of 14 weeks (range 4–24 weeks). Anti-TNF dose intensification using any strategy was more likely to result in tertiary response than tertiary non-response within the first 6 months (RR 2.58 [95% CI 1.76, 3.79, I² = 82%], Figure 3(a)).

**Evaluating tertiary response and tertiary LOR.** Seven studies reported both tertiary response and tertiary LOR beyond 6 months of infliximab (n = 4) or adalimumab (n = 3) dose intensification, including five studies that used dose intensification to address secondary LOR alone. Sustained tertiary response to anti-TNF dose intensification beyond 6 months (RR 1.10 [95% CI 0.75, 1.61, I² = 85%], Figure 3(b)) was comparable to tertiary LOR after a median of 12 months (range 9–23 months).

Potential sources of heterogeneity were evaluated by subgroup analysis, including by anti-TNF (infliximab, adalimumab or pooled infliximab/adalimumab) or indication for dose intensification (secondary LOR *versus* pooled primary non-response/secondary LOR). The results remained similar in all cases with no variations of significance, although heterogeneity remained high.

**Discussion**

This systematic review affirms that empiric anti-TNF dose intensification represents a clinically effective strategy to address secondary LOR to adalimumab and infliximab therapy in patients with Crohn’s disease. Short-term clinical response...
following any anti-TNF dose-intensification strategy to address secondary LOR within 12 weeks ranged from 33% to 90%, while sustained clinical response lasting at least 48 weeks ranged from 25% to 85%.4–6,15–17,19–29,31,32,38,43,45 Similarly, short-term clinical remission following any anti-TNF dose-intensification strategy to address secondary LOR was 16–67% within 12 weeks, while longer-term clinical remission was reported in 20–84%.7,15–17,20,22,26–29,38,39,42–45

Nevertheless, empiric anti-TNF dose intensification is not always effective, and even when effective, may not provide a durable clinical response. Hence, the current systematic review also evaluated tertiary non-response and tertiary LOR following anti-TNF dose-intensification strategy to address secondary LOR was 16–67% within 12 weeks, while longer-term clinical remission was reported in 20–84%.7,15–17,20,22,26–29,38,39,42–45

![Figure 3](https://example.com/figure3.jpg)

**Figure 3.** Forest plot comparison of: (a) tertiary response versus tertiary non-response within 6 months of anti-TNF dose intensification (b) tertiary response versus tertiary loss of response beyond 6 months of anti-TNF dose intensification.
diagnosis (16–40 years),\(^5\) strictureing/penetrating phenotype,\(^5,23\) absence of continuous (≥6 months) corticosteroid use within 5 years of dose intensification,\(^41\) LOR after ≥10 months of adalimumab,\(^24\) non-smoking status,\(^5\) lower baseline CDAI,\(^17\) lower baseline CRP,\(^5,24\) baseline albumin ≥3.8 g/dL,\(^16\) baseline serum infliximab trough levels ≥1 mg/mL,\(^16\) and plasma IL-6 levels ≤2.41 pg/mL.\(^16\) Other factors associated with clinical response included dose intensification using adalimumab 40 mg weekly rather than 80 mg 2-weekly,\(^24\) lower CDAI 4 weeks following dose intensification,\(^17\) and normalisation of CRP following dose intensification.\(^4\) Similarly, characteristics associated with tertiary non-response and tertiary LOR-included corticosteroid use at adalimumab induction,\(^23\) higher baseline CRP,\(^6,23,24\) and prior anti-TNF exposure,\(^23\) while adalimumab 40 mg weekly (versus adalimumab 80 mg 2 weekly),\(^24\) male sex,\(^7\) higher baseline albumin,\(^7\) and thiopurine co-therapy\(^7\) were all associated with more favourable outcomes.

This systematic review and meta-analysis is, to the best of our knowledge, the first to evaluate tertiary response, tertiary non-response, and tertiary LOR following empiric anti-TNF dose intensification undertaken specifically to address secondary LOR in patients with Crohn’s disease. Strengths of our study include the rigorous and extensive literature search, evaluation of both favourable and unfavourable post-intensification clinical outcomes, patient, disease and treatment characteristics associated with these outcomes, and evaluating post-intensification outcomes specific to secondary LOR; however, we also acknowledge several limitations. Methodological heterogeneity impacts the interpretation of the studied outcomes, including differences between studies relating to study design, study population, and analytical approaches. Moreover, while current treatment algorithms advocate that secondary LOR be defined by the presence of both clinical and objective disease activity prior to anti-TNF dose intensification, only 15 of 34 eligible studies included validated clinical indices in their definition of LOR, of which six studies also required objective disease activity prior to anti-TNF dose intensification. Hence, a lack of standardisation between definitions of secondary LOR and clinical outcomes following dose intensification, likely reduces the reliability of direct comparison between studies. This also highlights the current unmet need for a more standardised approach to clinical assessment of secondary LOR and/or clinical response following anti-TNF dose intensification.

There is accumulating evidence to suggest that the first biologic agent may offer the most favourable response; reflected by studies documenting that a greater proportion of patients require adalimumab and infliximab dose escalation with second and third-line therapy.\(^46\) This review noted that studies that reported outcomes following infliximab dose intensification were more likely to have included patients who were biologic experienced relative to studies that reported outcomes following adalimumab dose intensification across largely biologic naïve cohorts. However, the impact of prior biologic exposure on clinical outcomes, particularly tertiary response and tertiary non-response, following anti-TNF dose intensification was difficult to ascertain owing to incomplete reporting of prior biologic exposure across patient subsets who were dose intensified. For similar reasons, it was difficult to ascertain the comparative effectiveness of empiric anti-TNF dose intensification undertaken for primary non-response and secondary LOR across studies that reported pooled clinical outcomes.

Despite the clinical effectiveness of anti-TNF dose intensification based on clinical and/or objective disease assessment alone, strategies that incorporate anti-TNF drug levels at the time of secondary LOR have been purported to increase the likelihood of therapeutic success.\(^2,47,48\) This implies that the optimal clinical approach to secondary LOR involves assessment of clinical and objective disease activity in conjunction with anti-TNF trough levels; highlighting the need to update existing model of care to facilitate this approach. Our group has demonstrated the utility of a virtual biologic clinic-led approach in executing such a strategy; showcasing that a virtual clinic led model-of-care is supported by processes that promote more appropriate dose intensification and more frequent treatment success than standard outpatient care alone.\(^18\)

In conclusion, although empiric anti-TNF dose intensification is clinically effective in patients with Crohn’s disease, particularly within the first 6 months, a proportion of patients will fail to demonstrate short-term and/or sustained clinical response. This highlights the need for clinical reassessment following anti-TNF dose intensification, particularly beyond 6 months, to differentiate
between effective and ineffective dose-intensification strategies. The ideal paradigm for disease reassessment following dose intensification is yet to be fully elucidated in Crohn’s disease, but should accommodate early recognition of response and non-response to facilitate discontinuation of ineffective therapy in cases of tertiary non-response, and consideration of further therapeutic optimisation or switching in cases of partial or incomplete tertiary response, respectively. Such an approach embodies many of the principles central to the modern-day treat-to-target paradigm.

Acknowledgements
AS is supported by an Australian Government Research Training Programme (RTP) scholarship, Monash University Graduate Excellence Scholarship and Monash University Department of Medicine Postgraduate Faculty Award. PDC is supported by a National Health & Medical Research Council (NH&MRC) Early Career Fellowship

Author contributions
Ashish Srinivasan: Conceptualization; Data curation; Formal analysis; Methodology; Writing – original draft; Writing – review & editing.
Robert Gilmore: Data curation; Formal analysis; Methodology; Writing – review & editing.
Daniel van Langenberg: Conceptualization; Supervision; Writing – review & editing.
Peter De Cruz: Conceptualization; Methodology; Supervision; Writing – review & editing.

Conflict of interest statement
The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: AS has served as a speaker for Sandoz, and received research support from Pfizer. PDC has served as a consultant, an advisory board member, or a speaker for AbbVie, Baxter, Ferring, Janssen, Celltrion, Emerge Health, Shire, and Takeda, and received research support from Ferring, Shire, Janssen, AbbVie, and Takeda. DvL has received educational grants or research support from Pfizer, Takeda, Ferring, and Shire and has received consultancy and/or speaker’s fees from Pfizer, Janssen, AbbVie, Ferring, Vifor, and Emerge Health. RG has no disclosures.

Funding
The authors received no financial support for the research, authorship, and/or publication of this article.

Guarantor of the article
A/Prof Peter De Cruz.

ORCID iD
Ashish Srinivasan https://orcid.org/0000-0001-5952-1570

Supplemental material
Supplemental material for this article is available online.

References
1. Ben-Horin S and Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther 2011; 33: 987–995.
2. Yanai H and Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011; 106: 685–698.
3. Peyrin-Biroulet L, Deltenre P, De Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008; 6: 644–653.
4. Kopylov U, Mantzaris GJ, Katsanos KH, et al. The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximab. Aliment Pharmacol Ther 2011; 33: 349–357.
5. Katz L, Gisbert JP, Manoogian B, et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn’s disease patients with loss of response. Inflamm Bowel Dis 2012; 18: 2026–2033.
6. Baert F, Glorieux E, Reenaers C, et al. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn’s patients. J Crohns Colitis 2013; 7: 154–160.
7. Srinivasan A, Vasudevan A, McFarlane A, et al. Anti-TNF re-induction is as effective, simpler, and cheaper compared with dose interval shortening for secondary loss of response in Crohn’s disease. J Crohns Colitis 2018; 12: 280–288.
8. Mattoo VY, Basnayake C, Connell WR, et al. Systematic review: efficacy of escalated maintenance anti-tumour necrosis factor therapy in Crohn’s disease. Aliment Pharmacol Ther 2021; 54: 249–266.
9. Guberna L, Nyssen OP, Chaparro M, et al. Frequency and effectiveness of empirical anti-
TNF dose intensification in inflammatory bowel disease: systematic review with meta-analysis. *J Clin Med* 2021; 10: 2132.

10. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021; 372: n71.

11. Covidence. *Covidence systematic review software*. Melbourne, VIC, Australia: Veritas Health Innovation. http://www.covidence.org

12. Begg CB and Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* 1994; 50: 1088–1101.

13. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. *BMJ* 2011; 343: d5928.

14. Wells GA, Shea B, O’Connell D, et al. *The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses*. Oxford, 2000. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp

15. Steenholdt C, Brynskov J, Thomsen OØ, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial. *Gut* 2014; 63: 919–927.

16. Suzuki Y, Matsui T, Ito H, et al. Circulating interleukin 6 and albumin, and infliximab levels are good predictors of recovering efficacy after dose escalation infliximab therapy in patients with loss of response to treatment for Crohn’s disease: a prospective clinical trial. *Inflamm Bowel Dis* 2015; 21: 2114–2122.

17. Motoya S, Watanabe M, Wallace K, et al. Efficacy and safety of dose escalation to adalimumab 80 mg every other week in Japanese patients with Crohn’s disease who lost response to maintenance therapy. *Inflamm Intest Dis* 2017; 2: 228–235.

18. Srinivasan A, van Langenberg DR, Little RD, et al. A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn’s disease. *Aliment Pharmocol Ther* 2020; 51: 1342–1352.

19. Dreesen E, Van Stappen T, Ballet V, et al. Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn’s disease who lose clinical response. *Aliment Pharmocol Ther* 2018; 47: 346–355.

20. Nagata Y, Esaki M, Umeno J, et al. Therapeutic strategy for Crohn’s disease with a loss of response to infliximab: a single-center retrospective study. *Digestion* 2015; 91: 50–56.

21. Lin KK, Velayos F, Fisher E, et al. Durability of infliximab dose intensification in Crohn’s disease. *Dig Dis Sci* 2012; 57: 1013–1019.

22. Suzuki T, Mizoshita T, Sugiyama T, et al. Adalimumab dose-escalation therapy is effective in refractory Crohn’s disease patients with loss of response to adalimumab, especially in cases without previous infliximab treatment. *Case Rep Gastroenterol* 2019; 13: 37–49.

23. Ma C, Huang V, Fedorak D, et al. Adalimumab dose escalation is effective for managing secondary loss of response in Crohn’s disease. *Aliment Pharmocol Ther* 2014; 40: 1044–1055.

24. Duveau N, Nachury M, Gerard R, et al. Adalimumab dose escalation is effective and well tolerated in Crohn’s disease patients with secondary loss of response to adalimumab. *Dig Liver Dis* 2017; 49: 163–169.

25. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. *Gastroenterology* 2004; 126: 402–413.

26. Chaparro M, Panes J, García V, et al. Long-term durability of infliximab treatment in Crohn’s disease and efficacy of dose ‘escalation’ in patients losing response. *J Clin Gastroenterol* 2011; 45: 113–118.

27. Hibi T, Sakuraba A, Watanabe M, et al. Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn’s disease. *Inflamm Bowel Dis* 2012; 18: 1480–1487.

28. Chaparro M, Martinez-Montiel P, Van Domseelaar M, et al. Intensification of infliximab therapy in Crohn’s disease: efficacy and safety. *J Crohns Colitis* 2012; 6: 62–67.

29. Steenholdt C, Brynskov J, Thomsen OØ, et al. Individualized therapy is a long-term cost-effective method compared to dose intensification in Crohn’s disease patients failing infliximab. *Dig Dis Sci* 2015; 60: 2762–2770.

30. Hendlr SA, Cohen BL, Colombel J-F, et al. High-dose infliximab therapy in Crohn’s disease: clinical experience, safety, and efficacy. *J Crohns Colitis* 2015; 9: 266–275.

31. Colombel J-F, Sandborn WJ, Rutgeerts P, et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn’s disease: results from the CHARM trial. *Am J Gastroenterol* 2009; 104: 1170–1179.
32. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease. *Gastroenterology* 2009; 137: 1628–1640.

33. Bultman E, de Haar C, van Liere-Baron A, et al. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn’s disease patients. *Aliment Pharmacol Ther* 2012; 35: 335–341.

34. Panaccione R, Loftus EV, Binion D, et al. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn’s disease: results of the Adalimumab in Canadian SubjecTs with ModErate to Severe Crohn’s DiseaSe (ACCESS) trial. *Can J Gastroenterol* 2011; 25: 419–425.

35. Sandborn WJ, Colombel J-F, Schreiber S, et al. Dosage adjustment during long-term adalimumab treatment for Crohn’s disease: clinical efficacy and pharmacoeconomics. *Inflamm Bowel Dis* 2011; 17: 141–151.

36. Löfberg R, Louis EV, Reinisch W, et al. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn’s disease: results from CARE. *Inflamm Bowel Dis* 2012; 18: 1–9.

37. Watanabe M, Hibi T, Mostafa NM, et al. Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn’s disease. *J Crohns Colitis* 2014; 8: 1407–1416.

38. Bouguen G, Laharie D, Nancey S, et al. Efficacy and safety of adalimumab 80 mg weekly in luminal Crohn’s disease. *Inflamm Bowel Dis* 2015; 21: 1047–1053.

39. Restellini S, Chao C-Y, Lakatos PL, et al. Therapeutic drug monitoring guides the management of Crohn’s patients with secondary loss of response to adalimumab. *Inflamm Bowel Dis* 2018; 24: 1531–1538.

40. Verstockt B, Moors G, Bian S, et al. Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naïve Crohn’s disease patients: the usefulness of rapid testing. *Aliment Pharmacol Ther* 2018; 48: 731–739.

41. Ghaly S, Costello S, Beswick L, et al. Dose tailoring of anti-tumour necrosis factor-alpha therapy delivers useful clinical efficacy in Crohn’s disease patients experiencing loss of response. *Intern Med J* 2015; 45: 170–177.

42. Viazis N, Koukouratos T, Anastasiou J, et al. Azathioprine discontinuation earlier than 6 months in Crohn’s disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation. *Eur J Gastroenterol Hepatol* 2015; 27: 436–441.

43. Narula N, Kainz S, Petritsch W, et al. The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn’s disease. *Aliment Pharmacol Ther* 2016; 44: 170–180.

44. Preda C, Fulger L, Gheorghe L, et al. Adalimumab and infliximab in Crohn’s disease: real life data from a national retrospective cohort study. *Curr Health Sci J* 2016; 42: 115–124.

45. María del Carmen R, Chaparro M Mesonero F, et al. Effectiveness of anti-TNFα drugs in patients with Crohn’s disease who do not achieve remission with their first anti-TNFα agent. *Dig Liver Dis* 2016; 48: 613–619.

46. Einarson TR, Bereza BG, Ying Lee X, et al. Dose escalation of biologics in Crohn’s disease: critical review of observational studies. *Curr Med Res Opin* 2017; 33: 1433–1449.

47. Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. *Am J Gastroenterol* 2010; 105: 1133–1139.

48. Roblin X, Rinaudo M, Del Tedesco E, et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. *Am J Gastroenterol* 2014; 109: 1250–1256.